The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells

被引：0
|
作者：
G. Marroncini
C. Anceschi
L. Naldi
B. Fibbi
F. Baldanzi
M. Maggi
A. Peri
机构：
[1] AOU Careggi,Pituitary Diseases and Sodium Alterations Unit
[2] University of Florence,Endocrinology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”
[3] AOU Careggi,undefined
来源：
Journal of Endocrinological Investigation | 2022年 / 45卷
关键词：
Tolvaptan; AVP receptors; Hyponatremia; Cancer; SIAD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1693 / 1708
页数：15
相关论文
共 50 条
  • [31] Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure
    Suzuki, S.
    Yoshihisa, A.
    Abe, Y.
    Saito, T.
    Ohwada, T.
    Suzuki, H.
    Saitoh, S.
    Kubota, I.
    Takeishi, Y.
    EUROPEAN HEART JOURNAL, 2014, 35 : 160 - 161
  • [32] Vasopressin V2 Receptor Antagonist Tolvaptan Is Effective in Heart Failure Patients With Reduced Left Ventricular Systolic Function and Low Blood Pressure
    Suzuki, Satoshi
    Yoshihisa, Akiomi
    Yamaki, Takayoshi
    Sugimoto, Koichi
    Kunii, Hiroyuki
    Nakazato, Kazuhiko
    Abe, Yukihiko
    Saito, Tomiyoshi
    Ohwada, Takayuki
    Suzuki, Hitoshi
    Saitoh, Shu-ichi
    Kubota, Isao
    Takeishi, Yasuchika
    INTERNATIONAL HEART JOURNAL, 2015, 56 (02) : 213 - 218
  • [33] Vasopressin V2 receptor, tolvaptan, and ERK1/2 phosphorylation in the renal collecting duct
    Khan, Shaza
    Raghuram, Viswanathan
    Chen, Lihe
    Chou, Chung-Lin
    Yang, Chin-Rang
    Khundmiri, Syed J.
    Knepper, Mark A.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2024, 326 (01) : F57 - F68
  • [34] Three Cases of Tolvaptan, that is Vasopressin V2 Receptor Antagonisut, is Effective of Congestive Heart Failure
    Fujiwara, Syouhei
    Yuba, Masao
    Tateishi, Jun
    Masuyama, Tohru
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (09) : S166 - S166
  • [35] Use of tolvaptan, a new V2 receptor antagonist, in the treatment of syndrome of inappropriate antidiuretic hormone secretion (SIADH) secondary to small cell lung cancer (SCLC) - a case series
    Fraser, I. M.
    Brooke, A. M.
    Dorey, N. E.
    Toy, E. W.
    LUNG CANCER, 2014, 83 : S69 - S69
  • [36] Constitutive internalisation of the human V2 vasopressin receptor
    Hermosilla, R
    Schmidt, A
    Schwieger, I
    Oksche, A
    Schülein, R
    Wiesner, B
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R18 - R19
  • [37] Constitutive internalisation of the human V2 vasopressin receptor
    Hermosilla, R
    Schmidt, A
    Schwieger, I
    Oksche, A
    Schülein, R
    Wiesner, B
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R18 - R18
  • [38] Raynaud's phenomenon triggered by the vasopressin V2 receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjogren's syndrome
    Roca Oporto, F. J.
    Rocha, Jose L.
    CLINICAL KIDNEY JOURNAL, 2022, 15 (04) : 827 - 828
  • [39] Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, enhances aquaresis and renal hemodynamics compared to furosemide in mild to moderate heart failure
    Costello-Boerrigter, LC
    Burnett, JC
    Smith, WB
    Ouyang, J
    Zimmer, CA
    Orlandi, C
    EUROPEAN HEART JOURNAL, 2004, 25 : 451 - 451
  • [40] SELECTIVE VASOPRESSIN V2 RECEPTOR ANTAGONIST DRUGS FOR PATIENTS WITH CIRRHOSIS AND ASCITES
    Chavez-Tapia, N. C.
    Barrientos-Gutierrez, T.
    Santiago-Hernandez, J. J.
    Tellez-Avila, F.
    Mendez-Sanchez, N.
    Uribe, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S265 - S265
12345